Mice that were vaccinated with LNP-encapsulated ovalbumin (OVA) mRNA formulated with PAM3 and subsequently challenged with OVA-expressing mouse lymphoma cells exhibited a marked increase in OVA-specific CD8+ T cells, a diminution in tumor size, and an increased rate of survival compared to control groups. Here, CD8A is linked to neoplasm.